RESEARCH ARTICLE

Significance of serum FGF-23 for risk assessment of contrast-associated acute kidney injury and clinical outcomes in patients undergoing coronary angiography

Shao-Sung Huang1,2,3, Po-Hsun Huang1,4,5*, Hsin-Bang Leu1,2,5, Tao-Cheng Wu1,5, Jaw-Wen Chen1,2,3, Shing-Jong Lin1,2,5

1 Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2 Healthcare and Management Center, Taipei Veterans General Hospital, Taipei, Taiwan, 3 School of Medicine, National Yang Ming Chiao Tung University, Tainan City, Taiwan, 4 Department of Critical Care Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 5 Institute of Clinical Medicine, Cardiovascular Research Center, National Yang Ming Chiao Tung University, Tainan City, Taiwan

* huangbs@vghtpe.gov.tw

Abstract

Background
Fibroblast growth factor (FGF)-23 levels rise as kidney function declines. Whether elevated FGF-23 levels are associated with an increased risk for contrast-associated acute kidney injury (CA-AKI) and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography remain uncertain.

Methods
In total, 492 patients receiving coronary angiography were enrolled. Their serum FGF-23 levels were measured before administration of contrast media. The occurrence of CA-AKI was defined as a rise in serum creatinine of 0.5 mg/dL or a 25% increase from the baseline value within 48 h after the procedure. All patients were followed up for at least 1 year or until the occurrence of MACE including death, nonfatal myocardial infarction (MI), and ischemic stroke.

Results
Overall, CA-AKI occurred in 41 (8.3%) patients. During a median follow-up of 2.6 years, there were 24 deaths, 3 nonfatal MIs, and 7 ischemic strokes. Compared with those in the lowest FGF-23 tertile, individuals in the highest FGF-23 tertile had a significantly higher incidence of CA-AKI (P < 0.001) and lower incidence of MACE-free survival (P = 0.001). In multivariate regression analysis, higher FGF-23 level was found to be independently associated with a graded risk for CA-AKI (OR per doubling, 1.90; 95% CI 1.48–2.44) and MACE (HR per doubling, 1.25; 95% CI 1.02–1.52).
Conclusions
Elevated FGF-23 levels were associated with an increased risk for CA-AKI and future MACE among patients undergoing coronary angiography. FGF-23 may play a role in early diagnosis of CA-AKI and predicting clinical outcomes after coronary angiography.

Introduction
Contrast-induced nephropathy, also known as contrast-associated acute kidney injury (CA-AKI), remains a serious clinical problem associated with the use of iodinated contrast media in diagnostic imaging and interventional procedures [1, 2]. Several risk factors are associated with CA-AKI, including the pre-existence of renal dysfunction, hypotension, heart failure, diabetes mellitus, older age, anemia, and the amount and type of contrast media used [3–5]. Despite technological advances, the incidence of CA-AKI ranges from 1–2% in the general population to 50% in high-risk subgroups after coronary angiography or percutaneous coronary intervention (PCI) [6]. Although the exact pathophysiological mechanisms underlying CA-AKI are still unclear, multiple factors, including renal vasoconstriction, direct cytotoxic effects of contrast media, oxidative stress, inflammation, and tubular obstruction, are likely involved [7]. The development of CA-AKI after PCI has been associated with poor short- and long-term outcomes, including death resulting primarily from cardiovascular causes [8–10].

Fibroblast growth factor-23 (FGF-23) is a secreted, bone-derived hormone that plays a fundamental role in the regulation of phosphate and vitamin D homeostasis by stimulating urinary phosphate excretion and inhibiting the activation of vitamin D in the kidney [11, 12]. FGF-23 levels rise as renal function declines, and higher levels are strongly associated with increased risks of cardiovascular disease (CVD), heart failure, and progression to end-stage renal disease (ESRD) [13, 14]. In addition, elevated FGF-23 level has been shown to be an independent predictor of death in patients with chronic kidney disease (CKD) and ESRD [14, 15]. Recently, the association between FGF-23 levels and acute kidney injury (AKI) has also been studied. Patients with AKI show elevated FGF-23 levels, which are associated with a greater risk of death or need for renal replacement therapy [16]. Moreover, some clinical studies have described the relation between FGF-23 level and inflammatory markers. Mendoza et al. found that there is a positive association between levels of FGF-23 and IL-6, C-reactive protein (CRP), and TNF-α in patients with CKD [17]. Nasrallah et al. demonstrated that FGF-23 is strongly correlated with high-sensitivity CRP and advanced oxidation protein products in hemodialysis patients [18].

Given the role of oxidative stress and inflammation in the pathogenesis of CA-AKI and atherosclerosis, we hypothesized that elevated FGF-23 level is associated with a higher risk for CA-AKI and more cardiovascular events in patients undergoing coronary angiography. This study aimed to evaluate the relationship between serum FGF-23 levels and the incidence of CA-AKI, and to investigate the predictive role of FGF-23 in clinical outcomes of patients undergoing coronary angiography.

Methods
Study population
Between March 2011 and March 2015, a series of 492 consecutive patients who were admitted to a single medical center for elective coronary angiography were enrolled in this study. Before
enrollment, the medical record of each patient was reviewed in detail to collect data on medications, smoking status, and risk factors for CA-AKI such as age, pre-existing renal dysfunction, type 2 diabetes mellitus, and other comorbidities. Hypertension was defined as a systolic blood pressure $\geq 140$ mmHg, a diastolic blood pressure $\geq 90$ mmHg, or taking antihypertensive medications. Type 2 diabetes was defined as a fasting glucose $\geq 126$ mg/dL or use of anti-hyperglycemic agents. CKD was defined as an estimated glomerular filtration rate (eGFR) $< 60$ mL/min/1.73 m$^2$. eGFR was calculated using the modified glomerular filtration rate estimating equations for Chinese patients [19]. Body mass index (BMI) was calculated by dividing the weight of the patient in kilograms by the square of the height in meters. A history of CVD was established based on a self-reported history of heart failure, myocardial infarction (MI), or cerebrovascular accident. Patients were classified as former smokers only if they had not smoked for more than 6 months. Patients with a history or clinical evidence of renal failure during chronic peritoneal or hemodialytic treatment were excluded. Nonionic low-osmolar contrast media (iopromide) was administered intra-arterially for all patients, mainly through transradial catheters. Metformin and nephrotoxic agents such as NSAIDs were discontinued 48 hours prior to contrast media injection. Before and after contrast media exposure, isotonic (0.9%) saline was given intravenously at a rate of 1 mL/kg/h for 12 hours. In patients with reduced left ventricular function (ejection fraction $< 40\%$) or overt heart failure, the hydration rate was reduced to 0.5 mL/kg/h. All participants gave written informed consent, and the study protocol was approved by the institutional review board of Taipei Veterans General Hospital in Taipei, Taiwan.

**Laboratory investigations**

After an overnight fast for $\geq 8$ hours, blood samples were obtained from all patients before coronary angiography. Serum levels of CRP; glucose; calcium; phosphate; and lipid profiles including triglycerides, total cholesterol, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured using a Hitachi 7600 Autoanalyzer (Hitachi Ltd., Tokyo, Japan). Serum creatinine concentration (SCr) was measured at the time of admission, and every day for the following 3 days after contrast media exposure. Serum intact FGF-23 levels were measured using enzyme-linked immunosorbent assay (Merck Millipore). All samples were measured in duplicate, with an intra-assay coefficient of variation $< 10\%$. The patients were classified into tertiles based on the distribution of FGF-23 in the study sample. Patients with FGF-23 levels $> 15.1$ pg/mL (highest tertile) were defined as the high FGF-23 group (n = 164, 33.3%), those with FGF-23 levels $< 4.3$ pg/mL (lowest tertile) were defined as the low FGF-23 group (n = 166, 33.7%) and those with FGF-23 levels $\geq 4.3$ pg/mL and $\leq 15.1$ pg/mL were defined as the intermediate FGF-23 group (n = 162, 32.9%).

**Clinical follow-up for end points**

All patients were evaluated for the occurrence of CA-AKI, which was defined as the increment in SCr of 0.5 mg/dL or a 25% increase from the baseline value within 48 hours after coronary angiography. They were advised to visit the outpatient clinics regularly after discharge from the hospital. Besides, all patients were periodically contacted by telephone and their medical records were reviewed regularly until the occurrence of a major adverse kidney event (MAKE) which was a composite of death, the need for dialysis, or a persistent increase in SCr of at least 50% from baseline within the first 90 days after contrast media exposure, and a major adverse cardiovascular event (MACE) such as death, nonfatal MI, or ischemic stroke. Nonfatal MI was defined by elevated cardiac enzyme levels with ischemic symptoms and/or characteristic electrocardiographic changes. Ischemic stroke was defined as the presence of a new neurological
deficit lasting for at least 24 hours, with imaging evidence of a cerebrovascular accident confirmed by either computed tomography or magnetic resonance imaging.

Statistical analysis
Data were expressed in terms of mean and standard deviation (SD) for numeric variables and as the number (percent) for categorical variables. Continuous variables between groups were compared using Student’s *t*-test or one-way ANOVA. Subgroup comparisons of categorical variables were assessed using Chi-square or Fisher’s exact test. Logarithmic (log) transformation was performed to achieve normal distribution for skewed variable (CRP). Survival curves were generated using the Kaplan–Meier method, and survival among the groups was compared using the log-rank test. Multivariate logistic regression analysis was used to investigate the relationship between serum FGF-23 levels and the incidence of CA-AKI. Multivariate Cox regression analysis was used to evaluate the association of FGF-23 with clinical outcomes. The primary analyses evaluated FGF-23 tertiles using the lowest tertile as the reference category. FGF-23 was also evaluated as a continuous variable after log base 2 transformation, interpreted as “per doubling.” For CA-AKI, an initial model was adjusted for age and sex. A second model added hypertension, diabetes, prior heart failure, contrast volume, eGFR, serum CRP levels, and medications (loop diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers). For MACE, an initial model was adjusted for age and sex. A second model added the risk factors for CVD, including hypertension, diabetes, smoking, prior stroke, prior MI, prior heart failure, serum CRP levels, CA-AKI, eGFR, and cardiovascular medications (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins). The sample size was determined based on the need to detect the difference of incident CA-AKI between high and low FGF-23 groups with 80% power, using a cutoff for statistical significance of 0.05. Data were analyzed using SPSS version 17.0 (SPSS Inc, Chicago, IL). A *P* value <0.05 was considered to indicate statistical significance.

Results
Patient characteristics
The mean age of the 492 patients (331 males, 67%) was 68 ± 12 years. All patients were followed up until May 2016. None of them dropped out of the study, and all occurrences of adverse events were recorded. The baseline characteristics of the patients are shown in Table 1. There were no differences between the patients in the low FGF-23 group and those in the high FGF-23 group with respect to sex, BMI, smoking status, hypertension, serum levels of lipid profiles, fasting glucose and calcium, and contrast volume. However, compared with patients in the lowest FGF-23 tertile, those with higher FGF-23 levels were older, had a greater prevalence of type 2 diabetes and CKD, and were more likely to present with higher levels of serum phosphate and CRP at baseline. Individuals with higher FGF-23 levels also had a higher prevalence of prior heart failure, prior MI, and prior stroke/transient ischemic attack, and lower eGFR.

Effects of FGF-23 levels on CA-AKI, MAKE and MACE
All patients were successfully followed up for a mean duration of 33.1 ± 14.5 months (median 31.5 months; range, 27–1890 days). Of these, 41 (8.3%) developed CA-AKI after coronary angiography, and 20 (4.1%) developed MAKE. In addition, a total of 34 MACEs occurred, including 24 deaths, 3 nonfatal MIs, and 7 ischemic strokes.
Compared with patients without CA-AKI, those with CA-AKI had a higher prevalence of hypertension, type 2 diabetes, CKD, and heart failure, had lower eGFR, and were more likely to present with higher pre-procedural CRP levels. In addition, loop diuretics and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers were used more frequently at baseline in patients with CA-AKI than in those without CA-AKI (shown in S1 Table). As illustrated in Fig 1, individuals in the highest FGF-23 tertile had a significantly higher incidence of CA-AKI than that in patients in the lowest FGF-23 tertile (17.7% vs. 2.4%, \( P < 0.001 \)). In the high FGF-23 group, two of CA-AKI cases in which SCr doubled from baseline value. However, in the low and intermediate FGF-23 groups, none of CA-AKI cases in which SCr doubled from baseline value.

Moreover, there was a graded relationship of higher FGF-23 levels with higher event rates for each outcome except nonfatal MI, as shown in Table 2. The highest tertile of serum FGF-23 was strongly associated with higher risk of MAKE. Patients in the high FGF-23 group exhibited more cardiovascular deaths and all-cause mortality than those shown by patients in the low and intermediate FGF-23 groups. The incidence of MACE was significantly higher in patients with high FGF-23 levels than in those with low FGF-23 levels (12.2% vs. 2.4%, \( P = 0.002 \)). In order to investigate the potential impact of baseline FGF-23 levels on adverse event-free survival, Kaplan–Meier survival analysis was performed. Patients in the highest

| Table 1. Baseline characteristics of the study population by tertiles of FGF-23. |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                  | <4.3 pg/ml      | 4.3–15.1 pg/ml  | >15.1 pg/ml     | \( P \)         |
|-----------------|-----------------|-----------------|-----------------|-----------------|
| Age (years)     | 66.9 ± 11.9     | 67.7 ± 12.1     | 70.3 ± 13.0     | 0.032           |
| Male            | 116 (70)        | 113 (70)        | 102 (62)        | 0.236           |
| Body mass index (kg/m2) | 25.6 ± 3.8     | 25.8 ± 4.3     | 25.5 ± 4.8     | 0.910           |
| Current smoker  | 53 (32)         | 56 (35)         | 54 (33)         | 0.877           |
| Hypertension    | 105 (63)        | 106 (65)        | 114 (70)        | 0.476           |
| Diabetes mellitus | 49 (30)       | 48 (30)         | 68 (42)         | 0.031           |
| Chronic kidney disease | 34 (21)       | 36 (22)         | 78 (48)         | <0.001           |
| Prevalent HF and CVD |
| History of HF   | 12 (7)          | 9 (6)           | 25 (15)         | 0.006           |
| History of MI   | 4 (2)           | 9 (6)           | 14 (9)          | 0.050           |
| History of stroke/TIA | 4 (2)         | 8 (5)           | 14 (9)          | 0.044           |
| Lipid profiles (mg/dl) |
| Triglycerides   | 120 ± 73        | 119 ± 69        | 139 ± 113       | 0.064           |
| Total cholesterol | 166 ± 32       | 160 ± 32        | 165 ± 38        | 0.199           |
| High-density lipoprotein | 44 ± 12       | 42 ± 11         | 41 ± 14         | 0.106           |
| Low-density lipoprotein | 101 ± 27      | 95 ± 28         | 98 ± 30         | 0.282           |
| Fasting glucose (mg/dl) | 103 ± 33      | 104 ± 29        | 109 ± 35        | 0.203           |
| Serum phosphate (mg/dl) | 3.3 ± 0.6     | 3.3 ± 0.6       | 3.6 ± 0.9       | 0.033           |
| Serum calcium (mg/dl) | 9.0 ± 0.6      | 8.9 ± 0.5       | 8.9 ± 0.7       | 0.240           |
| C-reactive protein (mg/dl) | 0.24 ± 0.28   | 0.47 ± 0.68     | 0.94 ± 1.06     | <0.001           |
| eGFR (ml/min/1.73m²) | 74.5 ± 21.2    | 71.3 ± 18.2     | 62.2 ± 26.1     | <0.001           |
| Contrast volume (ml) | 100 ± 75       | 99 ± 72         | 97 ± 70         | 0.941           |

Values are mean ± SD or number (%).
HF: heart failure; CVD: cardiovascular disease; MI: myocardial infarction; TIA: transient ischemic attack; eGFR: estimated glomerular filtration rate.

https://doi.org/10.1371/journal.pone.0254835.t001
Fig 1. Incidence of contrast-associated acute kidney injury in patients stratified into 3 groups according to tertiles of FGF-23. $P < 0.001$.

https://doi.org/10.1371/journal.pone.0254835.g001

Table 2. Adverse events based on tertiles of serum FGF-23 levels.

|                     | FGF-23 Tertile |                     |                     |          |
|---------------------|----------------|---------------------|---------------------|----------|
|                     | $<4.3$ pg/ml   | $4.3–15.1$ pg/ml    | $>15.1$ pg/ml       | $P$      |
|                     | (n = 166)      | (n = 162)           | (n = 164)           |          |
| MAKE                | 2 (1.2)        | 5 (3.1)             | 13 (7.9)            | 0.007    |
| All-cause death     | 2 (1.2)        | 6 (3.7)             | 16 (9.8)            | 0.001    |
| Cardiovascular death| 0 (0)          | 3 (1.9)             | 7 (4.3)             | 0.023    |
| Nonfatal MI         | 1 (0.6)        | 2 (1.9)             | 0 (0)               | NS       |
| Ischemic stroke     | 1 (0.6)        | 2 (1.2)             | 4 (2.4)             | NS       |
| MACE (death/MI/stroke)| 4 (2.4)    | 10 (6.2)            | 20 (12.2)           | 0.002    |

Values are number (%).
MAKE: major adverse kidney event; MI: myocardial infarction; MACE: major adverse cardiovascular event.

https://doi.org/10.1371/journal.pone.0254835.t002
FGF-23 tertile showed a significantly lower incidence of MACE-free survival than that shown by patients in the lowest FGF-23 tertile ($P = 0.001$), as illustrated in Fig 2.

**Independent correlates of CA-AKI and predictors of MACE**

In order to investigate the association between FGF-23 and incident CA-AKI, multivariate logistic regression analysis was performed. Elevated FGF-23 levels remained significantly associated with a greater risk for CA-AKI after sequential multivariable adjustment, as shown in Table 3. Each doubling of FGF-23 levels was associated with a 103% higher risk in the primary model that adjusted for age and sex. The odds ratio (OR) comparing the highest versus the lowest tertile was 8.11 (95% confidence interval [CI], 2.76–23.82). In models that included other risk factors for CA-AKI, including hypertension, diabetes, prior heart failure, contrast volume, eGFR, log CRP, and medications (angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and loop diuretics), the highest versus lowest tertile of FGF-23 was associated with a 6.82-fold greater risk for CA-AKI (95% CI, 2.22–21.01), and a 90% higher risk per doubling of FGF-23 levels.

In order to investigate the independent predictors of future MACE, multivariate Cox regression analysis was performed. In unadjusted Cox models, each doubling of FGF-23 levels was associated with a 40% increased risk of MACE, and ascending FGF-23 tertiles were associated with a stepwise increase in risk, as shown in Table 3. The hazard ratio (HR) comparing the highest versus the lowest tertile was 5.71 (95% CI, 1.95–16.73). The significant graded risk of MACE across the spectrum of FGF-23 levels persisted in all multivariable models. Each doubling of FGF-23 levels was associated with a 37% higher risk in the primary model that adjusted for age and sex. In the model that included other CVD risk factors, the highest versus
lowest tertile of FGF-23 was associated with a 3.79-fold greater risk for MACE (95% CI, 1.20–11.99), and a 25% higher risk per doubling of FGF-23 levels.

**Discussion**

The major finding of the present study is that elevated serum FGF-23 levels were independently associated with the incidence of CA-AKI and future cardiovascular events in patients undergoing coronary angiography. A graded relationship of higher FGF-23 levels with higher event rates for each outcome was observed. Elevated FGF-23 levels were more strongly associated with the risk for developing CA-AKI than MACE. Our findings did support the potential of FGF-23 as a novel risk marker for CA-AKI.

The widely usage of contrast media for a multitude of radiological procedures, including diagnostic coronary angiography and PCI, has raised concerns about the increasing incidence of a potential complication known as CA-AKI. However, the exact mechanism underlying CA-AKI is still unclear, although several suggestions have been put forward. Intrarenal vasoconstriction, inflammation, generation of reactive oxygen species, and direct tubular toxicity leading to hypoxia of the outer medulla are generally accepted as the main factors in the pathophysiology of CA-AKI [7]. A previous study has demonstrated that elevated CRP levels are associated with endothelial injury and impaired vasodilation, which may lead to acute renal damage and progressive loss of kidney function [20]. Moreover, systemic inflammation could render the kidneys more vulnerable to local inflammatory processes elicited by the reabsorption of iodinated contrast medium following angiographic procedures, favoring the development of CA-AKI [21–23]. Recent clinical studies indicate that there is a significant independent association between pre-procedural CRP levels and the occurrence of CA-AKI in patients with stable coronary artery disease undergoing elective PCI [24] and in those with ST-segment elevation MI undergoing primary PCI [25]. Consistent with the findings of previous studies, our data showed that elevated baseline CRP values are associated with higher incidence of CA-AKI in patients undergoing coronary angiography.

FGF-23, a phosphaturic peptide hormone secreted by the osteoblasts, is an important regulator of phosphorus and vitamin D metabolism [11, 12]. Accumulating evidence has linked the
components of phosphate homeostasis to inflammation and oxidative stress. Higher FGF-23 levels are independently associated with higher levels of inflammatory markers in patients with CKD and with substantially greater odds of manifesting severe inflammation [17]. FGF-23 is strongly correlated with various markers of inflammation and oxidative stress in ESRD patients on hemodialysis [18]. Moreover, elevation of plasma FGF-23 levels has been observed in multiple studies of human AKI [26]. Brown et al. reported that FGF-23 is independently associated with a higher risk of AKI hospitalizations in community-dwelling elderly individuals [27]. Neyra et al. demonstrated that serum intact FGF-23 levels were significantly higher in critically ill patients with AKI compared with matched controls without AKI. Elevated serum intact FGF-23 levels were associated with an increased risk of MAKE in critically ill patients admitted to the ICU [28]. In the current study, we also found that individuals with higher FGF-23 levels had higher baseline levels of inflammatory marker CRP, and that the risk of CA-AKI and MAKE were significantly increased in patients with elevated FGF-23 levels. Although one small study has shown that serum FGF-23 may have certain value in early diagnosis of CA-AKI [29], the causal relationship between FGF-23 and the development of CA-AKI has not been established. Our findings indicated an association between serum FGF-23 levels and the occurrence of CA-AKI, suggesting the predictive role of FGF-23 in the development of CA-AKI in patients undergoing coronary angiography. Although we were unable to determine whether FGF-23 has a causative effect, the potential mechanisms described above may partly explain the correlation between FGF-23 levels and the occurrence of CA-AKI following exposure to contrast media. Further studies are warranted to clarify the mechanistic role of FGF-23 in CA-AKI.

Multiple studies have demonstrated that elevated FGF-23 levels are associated with major cardiovascular events and mortality in patients with CKD and ESRD [14, 15, 30, 31]. Elevated FGF-23 levels are also strongly associated with adverse outcomes in patients with AKI. Leaf et al. reported that plasma FGF-23 levels rise early and predict AKI and death in patients undergoing cardiac surgery [32]. Moreover, higher FGF-23 levels are independently associated with greater mortality in critically ill patients. It may be a promising novel biomarker of AKI, death, and other adverse outcomes in critically ill patients [33, 34]. Recently, the association of FGF-23 with mortality is extended to individuals with heart failure with preserved ejection fraction [35], and to populations with known prevalent CVD [36, 37]. In addition, FGF-23 is independently associated with all-cause death and incident heart failure in community-living older individuals [13]. A previously published meta-analysis showed that individuals with increased plasma FGF-23 levels might suffer a higher risk of all-cause mortality and cardiovascular mortality [38]. Our findings also indicated the role of FGF-23 in predicting long-term outcomes in patients with suspected coronary artery disease. Consistent with the results of previous studies, our results showed significantly increased incidence of MACE, mainly death, in patients with high FGF-23 levels than in those with low FGF-23 levels. Further, serum FGF-23 levels could be independently associated with the risk of future MACE among patients undergoing coronary angiography.

This study had some limitations that should be considered. First, the study population was relatively small, and all participants were of Asian ethnicity and were recruited from a single center. Further studies with a larger number of different participants are required to confirm our findings. Second, the measurements of mineral metabolism complementary to FGF-23 (serum calcitriol and klotho) were not available. Thus, we could not provide additional insights into another potential mechanism underlying the association between elevated FGF-23 levels and CA-AKI. Third, the weight of the composite outcomes (MAKE, MACE) is mostly driven by mortality. Finally, our results are observational in nature, so residual confounding may
Persist, and the causal effects of FGF-23 cannot be determined. Further studies are needed to clarify the exact interaction between FGF-23 and CA-AKI.

In conclusion, FGF-23 is likely signaling a worse health status in the FGF-23 upper-level group, since this group presented significantly more comorbidities (DM, CKD, previous MI and stroke) and more importantly, higher inflammation (higher CRP) and especially lower eGFR. Therefore, it is very likely that this worse health status was actually responsible for the results: greater CA-AKI and worse MACE. Nevertheless, our results show promise for testing this biomarker as part of novel risk prediction models of renal and cardiovascular outcomes in patients undergoing coronary angiography.

Supporting information

S1 Table. Baseline characteristics of patients with or without CA-AKI. (DOCX)

Author Contributions

Supervision: Hsin-Bang Leu, Tao-Cheng Wu, Jaw-Wen Chen, Shing-Jong Lin.

Writing – original draft: Shao-Sung Huang.

Writing – review & editing: Po-Hsun Huang.

References

1. McCullough PA, Soman SS. Contrast-induced nephropathy. Crit Care Clin 2005; 21:261–280. https://doi.org/10.1016/j.ccc.2004.12.003 PMID: 15781162

2. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. Am J Roentgenol 2004; 183:1673–1689. https://doi.org/10.2214/ajr.183.6.01831673 PMID: 15547209

3. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95:13–19. https://doi.org/10.1016/j.amjcard.2004.08.056 PMID: 15619387

4. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004; 44:1393–1399. https://doi.org/10.1016/j.jacc.2004.06.068 PMID: 15464318

5. Stacul F, van der Molen AJ, Reimer P, Webb JA, Thomsen HS, Morcos SK, et al; Contrast Media Safety Committee of European Society of Urogenital Radiology (ESUR). Contrast-induced nephropathy: updated ESUR Contrast Media Safety Committee guidelines. Eur Radiol 2011; 21:2527–2541. https://doi.org/10.1007/s00330-011-2225-0 PMID: 21866433

6. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl 2006;S11–15. https://doi.org/10.1038/sj.ki.5000368 PMID: 16612394

7. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al; CIN Consensus Working Panel. Pathophysiology of contrast-induced nephropathy. Am J Cardiol 2006; 98:14K–20K. https://doi.org/10.1016/s0002-9343(06)01040-0 PMID: 16949376

8. McCullough PA, Wolyn R, Rocher LL, Levin RN, O’Neill WW. Acute renal failure after coronary intervention: incidence, risk factors and relationship to mortality. Am J Med 1997; 103:368–375. https://doi.org/10.1016/s0002-9343(97)00150-2 PMID: 9375704

9. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous interventions. J Am Coll Cardiol 2002; 39:1113–1119. https://doi.org/10.1016/s0735-1097(02)01745-x PMID: 11923033

10. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105:2259–2264. https://doi.org/10.1161/01.cir.0000016043.87291.33 PMID: 12010907
11. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004; 19:429–435. https://doi.org/10.1359/JBMR.0301264 PMID: 15040831

12. Wolf M: Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82:737–747. https://doi.org/10.1038/ki.2012.176 PMID: 22622492

13. Ix JH, Katz R, Kestenbaum BR, de Boer IH, Chonchol M, Mukamal KJ, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: the Cardiovascular Health Study. J Am Coll Cardiol 2012; 60:200–207. https://doi.org/10.1016/j.jacc.2012.03.040 PMID: 22703926

14. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and death, heart failure, and cardiovascular events in patients with chronic kidney disease. JAMA 2011; 305:2432–2439. https://doi.org/10.1001/jama.2011.826 PMID: 21673295

15. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, et al. Fibroblast growth factor-23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359:584–592. https://doi.org/10.1056/NEJMoa0706130 PMID: 18687639

16. Leaf DE, Wolf M, Waikar SS, Chase H, Christov M, Cremers S, et al. FGF-23 levels in patients with AKI and risk of adverse outcomes. Clin J Am Soc Nephrol 2012; 7:1217–1223. https://doi.org/10.2215/CJN.00550112 PMID: 22700885

17. Mendoza JM, Isakova T, Ricardo AC, Xie H, Navaneethan SD, Anderson AH, et al; Chronic Renal Insufficiency Cohort. Fibroblast growth factor 23 and Inflammation in CKD. Clin J Am Soc Nephrol 2012; 7:1155–1162. https://doi.org/10.2215/CJN.12812111 PMID: 22554719

18. Nasrallah MM, El-Shehaby AR, Osman NA, Fayed T, Nassef A, Salem MM, et al. The Association between Fibroblast Growth Factor-23 and Vascular Calcification Is Mitigated by Inflammation Markers. Nephron Extra 2013; 3:106–112. https://doi.org/10.1159/000356118 PMID: 24348506

19. Ma YC, Luo Q, Chen JH, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006; 17:2937–2944. https://doi.org/10.1681/ASN.2006040368 PMID: 16988059

20. Tonelli M1, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68:237–245. https://doi.org/10.1111/j.1523-1755.2005.00398.x PMID: 15954913

21. Laskey WK, Gellman J. Inflammatory markers increase following exposure to radiographic contrast media. Acta Radiol 2003; 44:498–503. https://doi.org/10.1080/000329534 PMID: 14510756

22. McCullough PA. Contrast-induced acute kidney injury. J Am Coll Cardiol 2008; 51:1419–1428. https://doi.org/10.1016/j.jacc.2007.12.035 PMID: 18402894

23. Quintavalle C, Fiore D, De Micco F, Visconti G, Focaccio A, Golia B, et al. Impact of a high loading dose of atorvastatin on contrast-induced acute kidney injury. Circulation 2012; 126:3008–3016. https://doi.org/10.1161/CIRCULATIONAHA.112.103317 PMID: 23147173

24. Gao F, Zhou YJ, Zhu X, Wang ZJ, Yang SW, Shen H. C-reactive protein and the risk of contrast-induced acute kidney injury in patients undergoing percutaneous coronary intervention. Am J Nephrol 2011; 34:203–210. https://doi.org/10.1159/000329534 PMID: 21791916

25. Jian-Wei Z, Yu-Jie Z, Shu-Jun C, Qing Y, Shi-Wei Y, Bin N. Impact of preprocedural high-sensitivity C-reactive protein on contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology 2014; 65:402–407. https://doi.org/10.1177/0003319713482177 PMID: 23539615

26. Christov M, Neyra JA, Gupta S, Leaf DE. Fibroblast growth factor 23 and klotho in AKI. Semin Nephrol. 2019; 39:57–75. https://doi.org/10.1016/j.semnephrol.2018.10.005 PMID: 30606408

27. Brown JR, Katz R, Ix JH, de Boer IH, Siscovick DS, Grans ME, et al. Fibroblast growth factor 23 and the long-term risk of hospital-associated AKI among community-dwelling older individuals. Clin J Am Soc Nephrol. 2014; 9:239–246. https://doi.org/10.2215/CJN.05805113 PMID: 24262510

28. Neyra JA, Li X, Mescia F, Ortiz-Soriano V, Adams-Huet B, Pastor J, et al. Urine Klotho Is Lower in Critically Ill Patients With Versus Without Acute Kidney Injury and Associates With Major Adverse Kidney Events. Crit Care Explor. 2019; 1:e0016. https://doi.org/10.1077/0003319713482177 PMID: 32166260

29. Li Huihui, Yu Zaixin, Gan Lu, Peng Ling, Zhou Qiaoling. Serum NGAL and FGF23 may have certain value in early diagnosis of CIN. Ren Fail. 2018; 40:547–553. https://doi.org/10.1080/0886022X.2018.1487860 PMID: 30278796
30. Kendrick J, Cheung AK, Kaufman JS, Greene T, Roberts WL, Smits G, et al; HOST Investigators. FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol 2011; 22:1913–1922. https://doi.org/10.1681/ASN.2010121224 PMID: 21903574

31. Scialla JJ, Xie H, Rahman M, Anderson AH, Isakova T, Ojo A, et al; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25:349–360. https://doi.org/10.1681/ASN.2013050465 PMID: 24158986

32. Leaf DE, Christov M, Jüppner H, Siew E, Ikizler TA, Bian A, et al. Fibroblast growth factor 23 levels are elevated and associated with severe acute kidney injury and death following cardiac surgery. Kidney Int. 2016; 89:939–948. https://doi.org/10.1016/j.kint.2015.12.035 PMID: 26924052

33. Leaf DE, Jacob KA, Srivastava A, Chen ME, Christov M, Jüppner H, et al. Fibroblast Growth Factor 23 Levels Associate with AKI and Death in Critical Illness. J Am Soc Nephrol. 2017; 28:1877–1885. https://doi.org/10.1681/ASN.2016080836 PMID: 28028134

34. Leaf DE, Siew ED, Eisenga MF, Singh K, Mc Causland FR, Srivastava A, et al. Fibroblast Growth Factor 23 Associates with Death in Critically Ill Patients. Clin J Am Soc Nephrol. 2018; 13:531–541. https://doi.org/10.2215/CJN.10810917 PMID: 29519954

35. Kanagala P, Arnold JR, Khan JN, Singh A, Gulsin GS, Eltayeb M, et al. Fibroblast-growth-factor-23 in heart failure with preserved ejection fraction: relation to exercise capacity and outcomes. ESC Heart Fail. 2020; 7:4089–99. https://doi.org/10.1002/ehf2.13020 PMID: 32935918

36. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640–648. https://doi.org/10.7326/0003-4819-152-10-201005180-00004 PMID: 20479029

37. Bergmark BA, Udell JA, Morrow DA, Cannon CP, Steen DL, Jarolim P, et al. Association of Fibroblast Growth Factor 23 With Recurrent Cardiovascular Events in Patients After an Acute Coronary Syndrome: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Jun 1; 3(6):473–480. https://doi.org/10.1001/jamacardio.2018.0633 PMID: 29710336

38. Qin Z, Liu X, Song M, Zhou Q, Yu J, Zhou B, et al. Fibroblast growth factor 23 as a predictor of cardiovascular and all-cause mortality in prospective studies. Atherosclerosis. 2017; 261:1–11. https://doi.org/10.1016/j.atherosclerosis.2017.03.042 PMID: 28411494